Prospective, longitudinal, observational study of novel serum/plasma biomarkers of disease activity in patients with inflammatory bowel disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013750

Enrollment

Registered

2018-03-22

Start date

2018-03-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K50 K51 K52

Interventions

Group 1: Patients with chronic inflammatory bowel disease (Crohn's Disease, Ulcerative Colitis, Microscopic colitis), in whom a new anti-inflammatory treatment is started in routine management. Before

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Outpatient visit for study-independent medical reasons - Patients with a) Crohn's disease, b) Ulcerative Colitis, c) Microscopic colitis - Patients before therapy start with an (extended) anti-inflammatory treatment (5-ASA, Budesonid, Prednisolon, Azathioprin, Methotrexat, anti-TNF, Vedolizumab, Ustekinumab, Tofacitinib)

Exclusion criteria

Exclusion criteria: - Stoma - Diseases which prevent the patient from understanding the nature and the concept of the clinical trial - Indications that the patient will presumably not comply with the protocol (e.g. adherence problem)

Design outcomes

Primary

Measure	Time frame
Changes in biomarkers (laboratory analysis, serum samples) in patients who respond to treatment vs. non-responders and controls	—

Secondary

Measure	Time frame
Time to reach the change in biomarkers with respect to therapeutic goals	—

Countries

Germany

Contacts

Public ContactOliver Bachmann

MHH OE6810

bachmann.oliver@mh-hannover.de+495115326766

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026